Cohero Health adds another $1.5M to Series A with new backing from Samsung, Omron

By Heather Mack
Share

New York City-based Cohero Health, which develops connected health tools and technologies for chronic respiratory diseases, has closed on $10.5 million in Series A funding. This builds on the company’s earlier $9 million Series A round from late 2016, and the extra funding comes from new strategic investors Samsung Next and Omron Healthcare. With seed funding, this brings Cohero's total funding to just over $13 million.

Cohero Health makes an integrated respiratory disease management platform called BreatheSmart, which connects to the company’s FDA-cleared, smartphone-connected spirometer that tracks inhaler use, measures lung function, offers medication reminders and allows users to record symptoms and share the information with their doctor and family members. Cohero will use the supplementary funds from Samsung Next and Omron Healthcare to expand commercialization of the platform.

“BreatheSmart from Cohero Health provides both connected hardware and software as an integrated platform, with a high attention to usability – this is no easy feat,” Samsung Next Principal Amit Garg said in a statement. “We are especially impressed with how the team developed their range of mobile spirometers, which required significant work around manufacturing, clinical efficacy and regulatory approval.”

Cohero Health was founded in 2012 and now counts over 25 commercial deployments representing over 1 million covered patient lives. In addition to the BreatheSmart platform and mSpirometer, the company also makes a wireless add-on sensor called HeroTracker to record inhaler usage and a personal web dashboard called CoheroConnect.

“Samsung NEXT and Omron Healthcare support our mission to improve respiratory care through smart mobile devices. These leading technology companies have the scale and expertise that are invaluable to early stage companies like ours,” Cohero Health CEO and cofounder Melissa Manice said in a statement. “We see significant benefit in partnering with well-established organizations such as Samsung and Omron Healthcare, while we remain focused on achieving platform scalability through interoperability and effective respiratory stakeholder collaboration.”